Abstract
We report a case of a 41-year-old woman who developed pregnancy-associated pyoderma gangrenosum (PG) at 4 weeks gestation. She was initially treated with prednisone, however, due to lack of improvement and risk of systemic corticosteroids in pregnancy, underwent a prednisone taper and was initiated on certolizumab pegol (CZP). The patient experienced complete wound re-epithelialization 1 month after CZP initiation. She had no pregnancy complications except for prednisone-associated gestational diabetes and gave birth to a healthy baby. CZP is a tumour necrosis factor-inhibitor with negligible placental transfer and no known adverse effects in pregnancy. Its efficacy and safety for autoinflammatory dermatoses in pregnancy are very promising. This is the first case to report CZP treatment for PG in a pregnant patient.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 696-698 |
| Number of pages | 3 |
| Journal | JEADV Clinical Practice |
| Volume | 3 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jun 2024 |
Bibliographical note
Publisher Copyright:© 2023 The Authors. JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- biologics
- certolizumab pegol
- neutrophilic dermatosis
- pregnancy
- pyoderma gangrenosum
Fingerprint
Dive into the research topics of 'Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS